Loading...

Biotinylated Recombinant Human SIRPG (carrier-free)

Pricing & Availability
Regulatory Status
RUO
Other Names
CD172g, SIRPB2, SIRP-B2, bA77C3.1, SIRPgamma
Ave. Rating
Submit a Review
Product Citations
publications
A. Recom_-Human-SIRPG_1_CF.
Immobilized biotinylated human SIRPG on streptavidin coated plate binds to human CD47-Fc Chimera in a dose-dependent manner. ED50 for this effect is 7-35 ng/mL.
  • A. Recom_-Human-SIRPG_1_CF.
    Immobilized biotinylated human SIRPG on streptavidin coated plate binds to human CD47-Fc Chimera in a dose-dependent manner. ED50 for this effect is 7-35 ng/mL.
  • B. Recom_-Human-SIRPG_2_CF.
    Stability testing for biotinylated human SIRPG: Biotinylated human SIRPG was reconstituted in sterile water at 0.25 mg/mL and kept at 4°C for two weeks, another lyophilized vial was kept at -20°C before reconstitution and treated as control. After this procedure, the samples were tested for their ability to bind to human CD47-Fc Chimera in a dose-dependent manner. ED50 for this effect is 7-35 ng/mL.
Cat # Size Price Quantity Check Availability Save
596955 50 µg 312€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

SIRPG or SIRP-gamma or SIRPγ (signal-regulatory protein γ) is a receptor protein involved in the negative regulation of receptor tyrosine kinase coupled signaling processes. It has been suggested that SIRPG signaling may play an immunoregulatory role in maintaining peripheral immune tolerance and preventing autoimmunity. SIRPG which has the same ligand that is, CD47 as SIRPα, expressed on T cells and activated NK cells. SIRPG-CD47 interaction mediates cell-cell adhesion and supports APC-T cell contact, enhancing antigen presentation, the consequent T cell proliferation and cytokine secretion. It seems unlikely that SIRPG itself generates intracellular signals because it does not have any recognizable signaling motifs. Instead, SIRPG may trigger signaling of CD47 in APCs. Although SIRPG is the only member of the SIRP family with known T1D (type I diabetes) risk loci, other proteins found in this family, such as SIRPα and SIRPβ1, may also be involved in ‘Type 1 Diabetes’ pathogenesis. The high expression of SIRPG is significantly associated with both T1D and LP (Lichen planus, a common chronic inflammatory skin disease) and this upregulation of SIRPG may exacerbate disease progression by regulating immune responses, promoting inflammation and causing tissue damage.

Product Details
Technical Data Sheet (pdf)

Product Details

Source
Human SIRPG, amino acids Glu29-Pro360 (Accession # Q9P1W8.3), with a C-terminal 6xHis tag and an Avi tag was expressed in CHO cells.
Molecular Mass
The 353 amino acid recombinant protein has a predicted molecular mass of approximately 39.4 kD. The protein migrates approximately at 40-50 kD in SDS-PAGE in DTT-reducing and non-reducing conditions.
N-terminal
Sequence Analysis
The predicted N-terminal amino acid is Glu.
Purity
> 95%, as determined by Coomassie stained SDS-PAGE.
Formulation
Lyophilized from 0.22 µm filtered protein solution in PBS, pH 7.2 with 5% trehalose.
Endotoxin Level
Less than 0.1 EU per μg of protein as determined by the LAL method
Concentration
50 µg size, Lyophilized
Storage & Handling
Unopened vial can be stored between 2°C -4°C for up to two weeks and at -20°C or colder until the expiration date. Reconstitute lyophilized protein in sterile water preferably in sterile deionized water. Before reconstitution, make sure sterile water and the product are at room temperature. Quickly spin the vial or gently tap down on the vial to make sure the lyophilized product is at the bottom of the vial before opening. Use aseptic techniques to add the required volume of reconstitution buffer (sterile water) to the vial, to obtain the recommended stock concentration 250 μg/mL. Close the vial and leave at an ambient temperature for 15-20 minutes. Then gently invert the vial several times or until all the lyophilized product dissolves. Leave the vial at room temperature for another 15 minutes. If small particulates are still observed after 15 minutes, incubate at room temperature for an additional 30 minutes and leave the vial at 2°C - 8°C overnight. Next day, invert the vial several times or gently pipette the solution up and down before use. If needed, transfer the reconstituted stock solution to a sterile container for additional dilution to no less than 100 μg/mL. Small working aliquots in polypropylene tubes can be made after reconstitution and store the vials at -20°C or lower. Avoid freeze/thaw cycles. Carrier protein such as 0.2 - 1% endotoxin-free BSA or HSA can be added when preparing the stock solution. Aliquots can be stored between 2°C and 8°C for up to two weeks or stored at -20°C or colder for up to 3 months.
Activity
Immobilized biotinylated human SIRPG on streptavidin coated plate binds to human CD47-Fc Chimera in a dose-dependent manner. ED50 for this effect is 7-35 ng/mL.
Application

Bioassay
Application Notes

Our lyophilized proteins are validated in-house to maintain activity after shipping at ambient temperature and are backed by our 100% satisfaction guarantee. If you have any concerns, contact us at tech@biolegend.com.

Antigen Details

Structure
Monomer
Distribution

CD4+ T-cells, CD8+ T-cells, CD56-bright natural killer (NK) cells, CD20+ cells, and all activated NK cells

Function
T cell and NK cell activation, cell-cell adhesion, supports APC-T cell contact, enhance antigen presentation, T cell proliferation and cytokine secretion
Interaction
CD47 expressing cells
Ligand/Receptor
CD47
Bioactivity
Immobilized biotinylated human SIRPG on streptavidin coated plate binds to human CD47-Fc Chimera in a dose-dependent manner. ED50 for this effect is 7-35 ng/mL.
Cell Type
Antigen-presenting cells, Granulocytes, Monocytes
Molecular Family
CD Molecules
Antigen References
  1. Sharp RC, et al. 2021. Frontier Immunology. 12:739048.
  2. Ichigotani Y, et al. 2000. J. Hum. Genet. 45:378.
  3. Nettleship JE, et al. 2013. Crystal BMC Struct. Biol. 13:13.
  4. Sinha S, et al. 2018. Sci. Rep. 8:15440.
  5. Sinha S, et al. 2019. Clin. Immunol. 198:57.
  6. Sharp RC, et al. 2021. Front Immunol. 12:739048.
  7. Brooke G, et al. 2004. J. Immunol. 173: 2562.
  8. Piccio L, et al. 2005. Blood. 105:2421.
  9. Van Beek EM, et al. 2005. J. Immunol. 175: 7781.
  10. Wu Ji, et al. 2024. Medicine (Baltimore). 103:e40454.
Gene ID
55423 View all products for this Gene ID
UniProt
View information about SIRPG on UniProt.org

Related FAQs

There are no FAQs for this product.
Go To Top Version: 1    Revision Date: 07/21/2025

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account